Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 4/20 | 0.68 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.50 |
| ▸ | MCHR1 | Q99705 | 7/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3615399 | 0.85 | DRD2 (0.51) | OPRL1OPRM1CYP3A4 | |
| SCHEMBL3602780 | 0.82 | NPC1 (0.56) | OPRL1CYP3A4 | |
| SCHEMBL3604592 | 0.78 | CACNA1G (0.58) | OPRL1ACHEOPRM1SIGMAR1 | |
| SCHEMBL3617803 | 0.76 | OPRL1 (0.68) | OPRL1OPRM1 | |
| SCHEMBL1866442 | 0.75 | OPRL1 (0.55) | OPRL1ACHEOPRM1MCHR1 | |
| SCHEMBL4865936 | 0.74 | OPRL1 (0.54) | OPRL1OPRM1 | |
| SCHEMBL6165274 | 0.73 | OPRL1 (0.47) | OPRL1CYP3A4 | |
| SCHEMBL3612375 | 0.72 | OPRM1 (0.61) | OPRL1OPRM1 | |
| SCHEMBL3620583 | 0.72 | HTR4 (0.41) | OPRL1OPRM1 | |
| SCHEMBL7304448 | 0.71 | MCHR1 (0.65) | ACHEMCHR1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020128288-A1 | Useful in the treatment of chronic and acute pain. | PURDUE PHARMA L.P. | 2002-09-12 | — | — | US | claimed |
| US-7678809-B2 | Benzimidazole compounds having nociceptin receptor affinity | PURDUE PHARMA L.P. (US) | 2010-03-16 | — | — | US | disclosed |
| US-7456198-B2 | Useful in the treatment of chronic and acute pain. | PURDUE PHARMA L.P. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20060264638-A1 | Benzimidazole compounds having nociceptin receptor affinity | EURO-CELTIQUE S.A. (LU) | 2006-11-23 | — | — | US | disclosed |
| US-20020128288-A1 | Useful in the treatment of chronic and acute pain. | PURDUE PHARMA L.P. | 2002-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264638-A1 | Benzimidazole compounds having nociceptin receptor affinity | OPRL1, OPRK1, OGFRL1 | OPRL1 1/4885ACHE 343/4885OPRM1 5/4885 |
| US-20020128288-A1 | Useful in the treatment of chronic and acute pain. | OPRL1, OGFRL1, OPRK1 | OPRL1 1/4885ACHE 524/4885OPRM1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.